TG Therapeutics News

Peering Into TG Therapeutics's Recent Short Interest

TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 6.31% since its last report. The company recently reported that it has 35.71 million shares sold short, which is 25.55% of all regular s

BenzingaMay 14 09:30

TG Therapeutics Under Pressure: Navigating the Perils of Government Contracts and Compliance Hurdles

TipRanksMay 8 01:01

TG Therapeutics | 10-Q: Quarterly report

Futu NewsMay 6 16:00 · Announcements

New Forecasts: Here's What Analysts Think The Future Holds For TG Therapeutics, Inc. (NASDAQ:TGTX)

Shareholders in TG Therapeutics, Inc. (NASDAQ:TGTX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased their

Simply Wall StMay 6 05:08

Earnings Call Summary | TG Therapeutics(TGTX.US) Q1 2024 Earnings Conference

The following is a summary of the TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript:Financial Performance:TG Therapeutics reported total revenue for Q1 2024 of $63.5 million, with U.S. Bri

Futu NewsMay 3 12:21 · Conference Call

TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 3 08:33

Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More Optimistic

Yahoo FinanceMay 3 06:29

Why TG Therapeutics Stock Was Rocketing Higher This Week

The Motley FoolMay 3 04:56

TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript

TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 2 21:21

TG Therapeutics Price Target Raised to $49.00/Share From $45.00 by HC Wainwright & Co.

TG Therapeutics Price Target Raised to $49.00/Share From $45.00 by HC Wainwright & Co.

Dow JonesMay 2 12:38

HC Wainwright & Co. : TG Therapeutics (TGTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $45.00 to $49.00.

HC Wainwright & Co. : TG Therapeutics (TGTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $45.00 to $49.00.

Zhitong FinanceMay 2 12:30

TG Therapeutics Is Maintained at Buy by Ladenburg Thalmann

TG Therapeutics Is Maintained at Buy by Ladenburg Thalmann

Dow JonesMay 2 08:14

Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40

Ladenburg Thalmann analyst Matthew Kaplan maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $39 to $40.

BenzingaMay 2 08:04

TG Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 147.83% Ladenburg Thalmann $39 → $40 Maintains Buy 04/18/2024 178.81% HC Wainwright & Co. → $45

BenzingaMay 2 08:03

TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo FinanceMay 2 06:27

Sell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription Growth

TipRanksMay 2 04:25

Q1 2024 TG Therapeutics Inc Earnings Call

Yahoo FinanceMay 1 23:27

Hold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market Pressures

TipRanksMay 1 16:35

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter.AMD guided

BenzingaMay 1 12:01

Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday.Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported

BenzingaMay 1 09:27